Atlas Antibodies Announces Executive Transition

Executive Leadership Change

On November 1 2026, Atlas Antibodies disclosed a significant change in its executive leadership. Chief Executive Officer Dan Pitulia stepped down following an agreement with the board, and Morten Henneveld was named interim Chief Executive Officer. Henneveld brings a robust track record in the life‑science and medical device sectors, having previously served as CEO of GN Group, Chair of the Board at Zimmer Biomet, and Managing Director of Coloplast. Most recently, he led OssDsign, where he oversaw strategic restructuring and portfolio expansion.

Board Perspective

Chair Åsa Riisberg issued a statement acknowledging Henneveld’s appointment. She emphasized his proven ability to steer organizations through periods of strategic change, expressing confidence that his expertise will support Atlas Antibodies’ ongoing development programs and commercial initiatives. The board’s endorsement signals continuity of corporate governance and a clear commitment to advancing the company’s pipeline.

Comments from Patricia Industries

Thomas Kidane, Co‑Head of Patricia Industries, the parent company and majority shareholder, welcomed the transition. He expressed appreciation for Pitulia’s contributions during his tenure and conveyed optimism about Henneveld’s leadership. Kidane noted that Patricia Industries will continue to play a pivotal role in strategic oversight and resource allocation as Atlas Antibodies pursues its growth strategy.

Corporate Context

Atlas Antibodies specializes in the discovery and development of monoclonal antibodies for rare diseases and oncology indications. The company has a portfolio of clinical‑stage candidates, several of which have entered Phase 2 trials in 2025. The executive transition is positioned as a step toward the next phase of Atlas Antibodies’ growth strategy, which includes scaling clinical operations, securing additional partnerships, and pursuing regulatory approvals for its lead candidates.

Implications for Stakeholders

  • Investors: The appointment of an interim CEO with extensive industry experience is likely to reassure shareholders regarding operational continuity and strategic execution.
  • Patients & Healthcare Professionals: A stable leadership structure supports ongoing clinical development, potentially accelerating access to new therapeutic options.
  • Regulatory Bodies: Clear governance and experienced leadership may facilitate smoother interactions with regulatory agencies, ensuring adherence to safety and efficacy standards.

Contact Information

Patricia Industries’ communications team remains available for further inquiries regarding this leadership transition and its impact on Atlas Antibodies’ strategic trajectory.